Abstract

<i>cis</i>-Diamminedichloroplatinum­(II) (cisplatin) is able to interact with human superoxide dismutase (hSOD1) in the disulfide oxidized apo form with a dissociation constant of 37 ± 3 μM through binding cysteine 111 (Cys111) located at the edge of the subunit interface. It also binds to Cu<sub>2</sub>–Zn<sub>2</sub> and Zn<sub>2</sub>–Zn<sub>2</sub> forms of hSOD1. Cisplatin inhibits aggregation of demetalated oxidized hSOD1, and it is further able to dissolve and monomerize oxidized hSOD1 oligomers <i>in vitro</i> and <i>in cell</i>, thus indicating its potential as a leading compound for amyotrophic lateral sclerosis

    Similar works

    Full text

    thumbnail-image

    Available Versions